A Broad-Spectrum Infection Diagnostic that Detects Pathogen-Associated Molecular Patterns (PAMPs) in Whole Blood by Cartwright, Marc et al.
EBioMedicine 9 (2016) 217–227
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch PaperA Broad-Spectrum Infection Diagnostic that Detects Pathogen-Associated
Molecular Patterns (PAMPs) in Whole BloodMark Cartwright a,1, Martin Rottman a,b,1, Nathan I. Shapiro c, Benjamin Seiler a, Patrick Lombardo a,
Nazita Gamini a, Julie Tomolonis a, Alexander L. Watters a, Anna Waterhouse a, Dan Leslie a, Dana Bolgen a,
Amanda Graveline a, Joo H. Kang a, Tohid Didar a, Nikolaos Dimitrakakis a, David Cartwright a,
Michael Super a, Donald E. Ingber a,d,e,⁎
a Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, United States
b Hôpitaux Universitaires Paris Ile de France Ouest (AP-HP), UMR INSERM U1173-UFR SSSV Université de Versailles St Quentin en Yvelines, Montigny, France
c Department of Emergency Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States
d Vascular Biology Program, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States
e Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA, United States⁎ Corresponding author at: Wyss Institute at Harvard
Circle, Boston, MA 02115, United States.
E-mail address: don.ingber@wyss.harvard.edu (D.E. In
1 Authors were equal contributors.
http://dx.doi.org/10.1016/j.ebiom.2016.06.014
2352-3964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 2 May 2016
Received in revised form 8 June 2016
Accepted 9 June 2016
Available online 13 June 2016Background: Blood cultures, andmolecular diagnostic tests that directly detect pathogen DNA in blood, fail to de-
tect bloodstream infections in most infected patients. Thus, there is a need for a rapid test that can diagnose the
presence of infection to triage patients, guide therapy, and decrease the incidence of sepsis.
Methods: An Enzyme-Linked Lectin-Sorbent Assay (ELLecSA) that uses magnetic microbeads coated with an
engineered version of the human opsonin, Mannose Binding Lectin, containing the Fc immunoglobulin domain
linked to its carbohydrate recognition domain (FcMBL) was developed to quantify pathogen-associated molecular
patterns (PAMPs) in whole blood. This assay was tested in rats and pigs to explore whether it can detect infections
and monitor disease progression, and in prospectively enrolled, emergency room patients with suspected sepsis.
These resultswere also comparedwith data obtained fromnon-infected patientswith orwithout traumatic injuries.
Results: The FcMBL ELLecSAwas able to detect PAMPSpresent on, or released by, 85% of clinical isolates representing
47 of 55 different pathogen species, including the most common causes of sepsis. The PAMP assay rapidly (b1 h)
detected the presence of active infection in animals, even when blood cultures were negative and bacteriocidal an-
tibiotics were administered. In patients with suspected sepsis, the FcMBL ELLecSA detected infection in 55 of 67 pa-
tients with high sensitivity (N81%), speciﬁcity (N89%), and diagnostic accuracy of 0·87. It also distinguished
infection from trauma-related inﬂammation in the same patient cohorts with a higher speciﬁcity than the clinical
sepsis biomarker, C-reactive Protein.
Conclusion: The FcMBL ELLecSA-based PAMP assay offers a rapid, simple, sensitive and speciﬁc method for diagnos-
ing infections, evenwhen blood cultures are negative and antibiotic therapy has been initiated. It may help to triage
patients with suspected systemic infections, and serve as a companion diagnostic to guide administration of emerg-
ing dialysis-like sepsis therapies.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Infections that can trigger a systemic inﬂammatory response syn-
drome (SIRS) leading to sepsis due to the presence of pathogens or re-
leased toxins (Bone, 1992) are most commonly diagnosed using blood
cultures in combination with characteristic physiological alterations
(e.g., increased heart and respiratory rates, temperature, white bloodUniversity, CLSB5, 3 Blackfan
gber).
. This is an open access article undercells counts) (Angus and van der Poll, 2013; Yealy et al., 2014; Singer
et al., 2016). But only 15 to 30% of sepsis patients with documented in-
fection produce positive blood cultures, (Tsalik et al., 2012;
Gille-Johnson et al., 2013; Loonen et al., 2014; Knabl et al., 2016;
Bacconi et al., 2014) and even then it can often take days before deﬁni-
tive results are obtained.With the absence of direct biomarkers for sep-
sis, blood proteins involved in the host inﬂammatory response, such as
C-reactive protein (CRP) and procalcitonin (PCT), have been used to de-
tect infection and predict outcome in septic patients (Pierrakos and
Vincent, 2010; Chan and Gu, 2011). However, while rising levels of
the CRP and PCT correlate with an increased likelihood of infection
and sepsis severity, these tests produce a wide range of sensitivitiesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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none of these inﬂammatory biomarkers unequivocally distinguishes in-
fection-induced SIRS from sterile SIRS caused by burn injury (Seoane et
al., 2014), trauma (Wojtaszek et al., 2014) or surgery (Battistelli et al.,
2014). Other groups (e.g. Spectral Diagnostics) have developed assays
that measure pathogen-derived biomarkers (e.g., endotoxin), but they
have not gainedwidespread use (Marshall et al., 2004) possibly because
they only detect Gramnegative bacteria.More rapidmolecular diagnos-
tic assays (e.g., based on PCR and mass spectrometry) can identify spe-
ciﬁc types of pathogens, but MALDI mass spectrometry requires a
culture step (Idelevich et al., 2014) to expand the number of live path-
ogens to above 105 colony forming units (CFUs), which again limits its
use to the minority of patients who are culture positive (Tsalik et al.,
2012; Gille-Johnson et al., 2013). PCR-based methods, such as SeptiFast
(Roche, Diagnostics GmbH), hybcell® Pathogens (Anagnostics
Bioanalysis GmbH), and IRIDICA (Abbott Molecular) have been devel-
oped that can detect speciﬁc types of whole pathogens directly in
blood within 4–6 h. However, because they require the presence of
the pathogen DNA in blood, they fail to detect suspected bloodstream
infections in 60–90% of patients (Knabl et al., 2016; Bacconi et al.,
2014). The T2Candida Panel (T2 Biosytems) has demonstrated im-
proved high speciﬁcity and sensitivity for fungal infections, and it can
identify invasive candidiasis in blood culture negative patients
(Mylonakis et al., 2015). However, none of these tests can be used to de-
tect a broad spectrum of pathogens (i.e., Gram negative and positive
bacteria, fungi, viruses, and parasites) as well as the toxins they release
(e.g., endotoxin, lipoteichoic acid) that are largely responsible for trig-
gering the cytokine cascade that leads to SIRS and sepsis.
Tomeasure the presence of a wide range of pathogens directly from
blood sampleswe leveraged a recently developed engineered version of
the natural human blood opsonin, Mannose Binding Lectin, as a broad-
spectrumagent that can capture awide range of pathogens and released
toxins. This engineered protein contains the carbohydrate recognition
domain of Mannose Binding Lectin linked to the Fc portion of human
IgG1, and hence, it is known as FcMBL (Kang et al., 2014). FcMBL
binds many Pathogen-Associated Molecular Patterns (PAMPs),(Parlato
and Cavaillon, 2015) which are carbohydrate cell wall materials includ-
ing lipopolysaccharide endotoxin (LPS), lipoteichoic acid and outer
membrane vesicles, that are present on, or released by, various types
of live and dead pathogens, includingmore than 90 different Gramneg-
ative and positive bacteria, fungi, viruses, and parasites (Kang et al.,
2014; Schultz et al., 2008; Dommett et al., 2006). PAMP release can
occur spontaneously (e.g., with Escherichia coli), and it increases signif-
icantly when pathogens are killed by antibiotics (Didar et al., 2015) and
likely by immune cells aswell.Wepreviously showed that FcMBL can be
used in dialysis-like devices to efﬁciently remove living Staphylococcus
aureus and Escherichia coli bacteria as well as dead pathogens and cell
wall-derived LPS from blood in rats based on its carbohydrate binding
activity (Kang et al., 2014; Didar et al., 2015). Given its broad spectrum
binding capabilities, we set out here to develop a simple and rapid infec-
tion diagnostic based on the use of FcMBL to detect the presence of
PAMPs in whole blood of infected animals and human patients that
might be used in the future to triage patients, accelerate antibiotic ad-
ministration, and serve as a companion diagnostic to identify patients
with high levels of PAMPs for emerging dialysis-like sepsis therapies
(Basu et al., 2014; Tullis et al., 2010; Mitaka and Tomita, 2011; McCrea
et al., 2014).
2. Methods
2.1. Study design
2.1.1. Detection of blood-borne infections in animals
To determine whether the FcMBL ELLecSA can be used to monitor
disease progression in vivo,we used twomodels of E. coli infection— in-
travenous bolus injection in Juvenile Yorkshire swine with analysis ofserial blood samples and intraperitoneal injection in rats that received
antibiotic therapy. Study approvals (pig protocol number 14-03-2519;
rat protocol number 13-12-2547R)were obtained from the Institutional
Animal Care and Use Committee (IACUC) of Boston Children's Hospital,
Harvard Medical School, the Animal Care and Use Review Ofﬁce
(ACURO) of the US Army Medical Research and Material Command
(USAMRMC) Ofﬁce, and Department of Defense (DOD). All studies
were conducted in accordance with the guidelines outlined in The
Guide for the Care and Use of Laboratory Animals, in an AAALAC-
accredited, USDA registered facility.
In the pig studies, animals were sedated and maintained on inhaled
anesthetics during surgical procedures to place intravenous lines, and
they were given appropriate analgesics to last for the entire study dura-
tion prior to recovery. For the infection study, E. coli 41949 pathogen ob-
tained fromahuman clinical isolatewas infused via the jugular vein into
female Yorkshire Swine, 30–50 kg (n=2 for each time point). Animals
were randomly assigned and no blinding was performed. Animals re-
ceived an initial dose of bacteria (0·5 × 107 CFU/kg) at the start of the
experiment (T = 0 h) followed by a 6 h infusion of 5·0 × 107 CFU/kg
(T= 3 to 9 h). Blood samples were drawn at intervals throughout the
study for blood culture in a BD™ Bactec™Media System (Standard/10
Aerobic/F vials), as well as for complete blood count (CBC, Abaxis) and
FcMBL ELLecSA.When the study was terminated at 35 h, organ samples
(liver, lungs, spleen) were harvested using sterile technique and proc-
essed for organ culture. For the vehicle control, swine (n= 2) received
saline with no E. coli and blood samples were drawn at the indicated
time points over a 24 h period.
To determine the efﬁcacy of the ELLecSA in the presence of antibiotic
treatments, rats (Wistar male ~ 370 g; Charles River Laboratories, USA)
were injected intraperitoneally with 2 × 109 CFU of E. coli (ATCC No.
8739). Rats were randomly assigned to antibiotic treatment (n = 6)
or saline control (n = 6) with no blinding performed. Infection was
allowed to proceed for 4 h before treatment with cefepime at 60 mg/
kg or saline control. Animalswere sacriﬁced 8 h after infection and a ter-
minal blood draw was performed and analyzed.
2.1.2. Sepsis diagnosis in humans: study design and patient enrollment
To assess the potential value of the FcMBL ELLecSA as a diagnostic
assay of infection and sepsis, we analyzed blood samples collected
from patients who were clinically suspected to have sepsis in the Beth
Israel Deaconess Medical Center (BIDMC) Emergency Department. All
patients provided informed consent and approval was granted by the
BIDMC Committee on clinical investigations. PAMP levels in the blood
of patients were assessed using the FcMBL ELLecSA and results were
compared with those from analysis of two control patient cohorts —
non-infected healthy blood donors and non-infected hospital patients
presenting with traumatic injuries. The patient enrollment is summa-
rized in Fig. 1.
To compare the sensitivity of our diagnostic with that of standard
blood cultures, minimum patient enrollment was determined using
the following assumptions: assuming 60% of patients are discordant
on the two tests (positive on one and negative on the other), 40 patients
provide 80%power to observe a difference between the tests of 35% (i.e.,
rate of positive on ﬁrst, negative on second of 47.5% and rate of negative
on ﬁrst and positive on second of 12.5%) or largerwith a two-sided, 0.05
level McNemar's test (of correlated proportions on the same patients).
We recruited the sepsis population from the Beth Israel Deaconess
Medical Center Emergency Department. Study inclusion criteria for
the sepsis population were: 1) adult patients (age 18 years or older)
who exhibited sepsis, as deﬁned by the presence of an infection (deter-
mined by the clinical treating team) and the presence of at least two
SIRS criteria using a modiﬁed deﬁnition of the American College of
Chest Physicians/Society of Critical Care Medicine.(Bone, 1992; Singer
et al., 2016) The SIRS criteria include: temperature N 100.4 °F or
b96.8 °F, heart rate N 90 beats/min, respiratory rate N 20 breaths/min
or partial pressure of carbon dioxide b32 mm Hg, and white blood cell
Fig. 1. Patient enrollment. Out of the total of 291 patients enrolled, 126were excludeddue
to blood samples being stored for longer than 24 h or results of assays notmeeting internal
validation of 95% conﬁdence interval of slope and background determined from the curve
ﬁt analysis of the internal mannan standard (see Supplemental Fig. 1). Of the remaining
165 patients, 78 sepsis patients (67 who entered the study at time 0, and 34 at 24 h [11
patients enrolled at 24 h]), 35 non-infected control patients without evidence of
infection or trauma (n = 23 hospital controls and n = 12 healthy volunteers), and 52
patients with trauma but no clinical suspicion of infection were analyzed.
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ed control population was similarly recruited from the emergency de-
partment where patients had to meet the following criteria: 1) adult
(N18 years old) 2) absence of infection, and 3) absence of meeting
two or more SIRS criteria. We also recruited trauma patients who
were adult emergency department patients with a traumatic injury
(long bone fracture or hollow viscous injury) without documented in-
fection. Approval for the use of additional non-infected human control
blood samples was obtained from Harvard University Faculty of Medi-
cine Committee on Human Studies (protocol number M20403-101).
This fourth group was blood donors who were healthy volunteers
who had provided informed consent, were nonsmokers, and had not
taken aspirin for the 2 weeks before donation.
3. Procedures
3.1. Microbiology
Mannan (Catalogue no. M3640) and LPS from E. coli O111:B4 (Cat.
no. L2630)were acquired from SigmaAldrich (Sigma Aldrich, USA). Ad-
ditional chemicalswere purchased from SigmaAldrich (MN, USA). Clin-
ical bacteria isolates were acquired from Brigham and Women’s
Hospital Crimson Biorepository, Beth Israel Deaconess Medical Center,
and Boston Children's Hospital, Boston, USA; BEI Resources, and ATCC
Bethesda, USA; and Hospital Joseph-Ducuing, Toulouse, France. All
strains were reviewed, and research was approved by Harvard's Com-
mittee on Microbiological Safety (COMS). Bacteria were cultured in
RPMI media (ThermoFisher, USA) supplemented with 10 mM Glucose
(Sigma Aldrich, USA) to a 0.5 McFarland (McF) standard (Becton Dick-
inson, USA). RPMI 10 mM glucose was chosen because MBL binds the
yeast extract present in traditional bacterial culture media (data not
shown).
For screening, bacteria were fragmented by either bead mill treat-
ment at 30 Hz for 10 min using 0.1 mm zirconia/silica beads (BioSpec
Products, USA) in a Mixer Mill MM 400 machine (Verder Scientiﬁc,
Inc., USA) or by treatment with antibiotic (100 μg/ml cefepime,
250 μg/ml amikacin, or 50 μg/ml meropenem) for a minimum of 4 h at
37 °C. FcMBL ELLecSA detection was performed on bead-milled or anti-
biotic-treated bacteria titered in TBST 5 mM Ca2+ (Boston Bioproducts,
USA).
In animal infection models, E. coli bacteria were diluted to desired
concentration in saline/dextrose, and the viability/quantity of the bacte-
ria conﬁrmed by plating, BacLight (Thermo Fisher, USA) live dead stain,and Bactiter™ (Promega,MI, USA). Endotoxin content of injectable bac-
teria was determined by Endoscan™ (Charles River Labs, USA).3.2. Enzyme-Linked Lectin-Sorbent Assay (ELLecSA)
The FcMBL-based ELLecSA leverages the engineered FcMBL previ-
ously described (Kang et al., 2014). A diagrammatical representation
of the FcMBL-ELLecSA detection of PAMPs fromwhole blood is outlined
in Fig. 2a. In brief, 200 μl of sample is added to 800 μl assay solution con-
taining 5 μg FcMBL-couple MyOne Dynabeads (Invitrogen, USA) at
5 mg/ml with 10 mM glucose, 50 μl heparin sulfate and TBST 5 mM
Ca2+. Samples are incubated for 20 min at 25 °C and the FcMBL-beads
with bound PAMPs are collected using a KingFisher Flex™ (Thermo
Fisher Scientiﬁc, Waltham, MA. USA) automated magnetic collection
device. Captured PAMPs are washed three times in TBST Ca2+ and de-
tected with rhMBL-horse radish peroxidase (HRP) kindly provided by
K. Takahashi. The unbound rhMBL-HRP is removed by 4 washes with
TBST 5 mM Ca2+ and PAMP detection is visualized by incubation in
tetramethylbenzidine (1-stepTMUltra TMB-ELISA, Cat no. 34028; Ther-
mo Fisher, Waltham MA, USA). TMB development is terminated with
1 M sulphuric acid, and the optical density is determined at 450 nm
wavelength. PAMP levels (PAMP units) are presented as FcMBL binding
units, which are determined by comparing optical density (450 nm)
measurements of FcMBL bound materials and comparing them to re-
sults obtained by carrying out an internal mannan standard curve (Fig.
2b); 1 PAMP unit was determined as being equivalent to 1 ng/ml man-
nan binding.3.3. Analysis of CRP as a comparator biomarker
CRP levels were measured in plasma using the Human SimpleStep
ELISA (Abcam, UK). Sensitivity and speciﬁcity were determined using
the manufacturer's criteria for elevated blood CRP levels (N5 μg/ml);
each sample was run in duplicate.3.4. Statistical analysis
All measured values are reported as the average of at least two sam-
ples ± standard deviation (SD) or means ± standard error of the mean
(SEM) as indicated in the ﬁgure legends. Signiﬁcant differences be-
tween groups with equivalent n values were determined using an un-
paired t-test, with p b 0·05 being considered to be signiﬁcant.
Signiﬁcant differences between groups of unpaired sample were calcu-
lated byWilcoxon Rank Sumanalysis and deﬁned as p values b 0.05. Sig-
niﬁcant differences between groups of paired samples were calculated
by Wilcoxon Signed Rank Test analysis with p b 0.05. Sensitivity and
speciﬁcity of each assay were determined by Receiver Operator Charac-
teristics (ROC); area under the curve and standard error of the mean
with p b 0.05. The ROC area under the curvewas used to report diagnos-
tic accuracy. Intra-assay coefﬁcients of variation in blood were deter-
mined for low (negative b 0.45 PAMP units) samples (n = 21) and
high (positive N 2.25 PAMP units) samples (n=25). Inter-assay coefﬁ-
cients of variation of low (negative = 0 PAMP units) and high (posi-
tive = 4 PAMP units) signals were determined from standard curve
data (n= 20).3.5. Funding
Defense Advanced Research Projects Agency (DARPA) grant
N66001-11-1-4180 and the Wyss Institute for Biologically Inspired En-
gineering at Harvard University. The funding sources had no role in the
study design.
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4.1. FcMBL ELLecSA
Todirectly quantify cellwall-derived PAMPs fromboth live anddead
pathogens in whole blood, we developed a modiﬁed version of a sand-
wich Enzyme-Linked Immuno-Sorbent Assay (ELISA) in which the
PAMP-binding lectin FcMBL(Kang et al., 2014) is used instead of an an-
tibody immunosorbent. In this Enzyme-Linked Lectin-Sorbent Assay
(ELLecSA), superparamagnetic microbeads (1 μm diameter) coated
with FcMBL are used to capture and magnetically collect PAMPs from
a small volume (200 μl) of whole human blood; the captured PAMPs
are then detectedwithin 1 h after sample collection by adding horserad-
ish peroxidase (HRP)-labeled recombinant human MBL (rhMBL) (Fig.
2a) using an automated, high throughput (96 well), Kingﬁsher analyti-
cal platform (Thermo Fisher Scientiﬁc, Waltham, MA. USA). Bound
PAMPs were quantiﬁed by comparing results to an internal standard
curve generated using the puriﬁed PAMP, yeastmannan,which is a pro-
totypic carbohydrate ligand for MBL (Super et al., 1989). The FcMBL
ELLecSA revealed a 1 ng/ml sensitivity for puriﬁed mannan in buffer
that was used to generate a standard PAMP binding curve (Fig. 2b).Fig. 2.Development of the FcMBL-based infection diagnostic. (a) Schematic representation of th
captured using FcMBL-coated magnetic microbeads (FcMBL-beads) in combination with applie
MBL linked to horse radish peroxidase (rhMBL-HRP), followed by addition of the chromogenic
samples. (b) Mannan standard curve showing FcMBL binding to mannanmeasured as optical d
FcMBL binding to 1 ng/ ml mannan). Graph showing detection of the carbohydrate PAMP LP
detection of Klebsiella oxytoca (d), Klebsiella pneumonia (e), Enterobacter cloacae (f), and Es
without (light grey) mechanical disruption (30 Hz for 10 min in a beadmill) or treatment wit
Unpaired t-test); data are presented as PAMP units. Bacteria were cultured in RPMI/10% GlucoThe limit of detection of the FcMBL ELLecSA for LPS spiked into human
whole blood was determined to be 0.3 PAMP units, which corresponds
to 15 ng/ml LPS (Fig. 2c). Thus, the FcMBL ELLecSA can rapidly detect
PAMPs in blood using small volumes in a high throughput format.
4.2. Broad spectrum detection of bacterial PAMPs
Native MBL has been reported to bind to PAMPs present on the sur-
faces of a wide variety of microbes,(Dommett et al., 2006) yet various
laboratories claim different binding afﬁnities to even common bacteria,
such as Escherichia coli (Jack and Turner, 2003). To assess the FcMBL
ELLecSA's ability to directly detect membrane PAMPs released into pa-
tient blood from a broad range of pathogenic bacteria, we ﬁrst screened
multiple pathogens, both when living and after they were destroyed
using either bead milling or antibiotics that are often administered to
patients as soon as a systemic infection is suspected based on clinical
presentation. The FcMBL ELLecSA detected over 85% (47 out of 55) of
the living pathogen species tested in the 1 h assay. Past studies sug-
gested that intact MBL showed variable binding to certain Gram nega-
tive pathogens,(Jack et al., 1998; Jack and Turner, 2003) and similarly,
we found that only 61% (98 out of 163) of intact bacterial isolatese FcMBL ELLecSAmethodology inwhich PAMPs orwhole pathogens contained in blood are
d magnetic ﬁelds, and detection of bound material by application of recombinant human
substrate, tetramethylbenzidine (TMB), which generates a positive signal in infected blood
ensity at 450 nm, which was used to determine PAMP units (1 PAMP unit is equivalent to
S (c) when diluted in whole blood using the FcMBL ELLecSA. Graphs showing enhanced
cherichia coli (g) bacteria using the FcMBL ELLecSA in combination with (dark grey) or
h the antibiotic cefepime (100 μg/ml) (f) or amikacin (250 μg/ml) for 4 h (g) (* p b 0.05;
se from a single colony and harvested at log phase (to 0.5 McF; 108 CFU/ml).
Table 1
Binding of clinical pathogen isolates by FcMBL. Testing of FcMBL bindingwas carried out using either intact living bacteria (1 × 107 CFU; live) or fungi (1 × 106 CFU) or a similar number of
bacteria that were treated with either a bacteriocidal antibiotic (cefepime 100 μg/ml or meropenem 50 μg/ml for 4 h; ABX) or mechanical disruption using a beadmill (30 Hz, 10 min) to
release PAMP-containing fragments. The genus, species, total number of clinical isolates screened for each bacterial species (# of isolates), and the number of live isolates (live detected)
and fragmented isolates (fragmented detected) identiﬁed by FcMBL ELLecSA are shown. The inset shows the total number of Escherichia coli isolates that were detected with the FcMBL
ELLecSA, and the number and percent of these isolates that were detected as living organisms (live) or fragmented. NT indicates not tested.
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cally disrupted the pathogens, or treated them with a bacteriocidal
beta-lactamantibiotic (cefepime) that disrupts the cell wall and thereby
exposes or releases previously hidden carbohydrate PAMPs,(Hurley,
1992) we were then able to measure membrane PAMPs released by
Klebsiella oxytoca, Klebsiella pneumoniae and Enterobacter cloacae that
displayed only weak FcMBL binding when intact (Fig. 2d–f). The levels
of FcMBL-bound PAMP materials released by similarly treated clinical
isolates of Escherichia coli also enabled us to increase detection of the
presence of the pathogen from 38% to 92% (Table 1). Similar responses
were obtained with another class of antibiotic that acts by inhibiting
protein synthesis (the aminoglycoside, amikacin; Fig. 2g), showing
that the FcMBL ELLecSA's can detect an increase in exposed or released
wall-associated PAMPs even when a bacteriocidal antibiotic does not
act by directly targeting the bacterial cell wall. Importantly, the FcMBLELLecSA was able to detect PAMPs released from 85% of all clinical iso-
lates tested encompassing 14 of 16 bacterial species that have been
found to be most commonly associated with sepsis based on positive
blood cultures at the Brigham and Women's Hospital in Boston and
Johns Hopkins School of Medicine in Baltimore (Supplemental Table 1).
4.3. Detection of blood-borne infection in vivo using the FcMBL ELLecSA
To determine whether the FcMBL ELLecSA can be used to monitor
clinical disease progression, we infected pigs with an intravenous
bolus of a clinical isolate of Escherichia coli. Serial blood samples were
drawn, and results from the FcMBL ELLecSA were compared with
those of traditional blood culture, post-mortem organ cultures, and
total white blood cell (WBC) count. A seen in human sepsis, the pig
blood cultures were initially positive, but rapidly became negative as
Table 2
Baseline characteristics of patients.
Baseline patient characteristics
Sepsis Non-infected
control
Non-infected
trauma
Number of patients 78 35 52
Age 61.5
(STD15.7)
35.7 (STD19.2) 61.8 (20.2)
Female gender (%) 44% 62% 67%
Severe sepsis 78% NA NA
Septic shock 29% NA NA
Blood culture
positive
12 0 2
Sofa score (range) 3.1 (STD2.8) NA NA
Mortality (%) 6.8% 0% 1.9%
Fig. 3. Detection of infection in animals by measuring PAMPs in blood using the FcMBL ELLecSA. a) Graph showing PAMP levels measured with the FcMBL ELLecSA (open circles) versus
white blood cell (WBC) counts (open triangles) and positive blood culture results (grey shaded area) and in samples obtained from pigs injected with Escherichia coli (0.5 × 107 CFU/kg)
and then infusedwith E. coli (5 × 107 CFU/kg) over 6 h or vehicle (no E. coli) at the start of the 36 h experiment. b) Pathogen loadsmeasured in cultures of lung, liver, and spleen after the
organswere removed at the end of the study and bead-milled to release harbored bacteria (4 different regions of each organwere processed, and pathogen loads are normalized per gram
of organ tissue). c) Rats were infected intraperitoneally with Escherichia coli (2 × 109 CFU) and then treated with the antibiotic cefepime (60mg/kg) starting 4 h after pathogen injection.
The FcMBL ELLecSAwas used tomeasure released PAMPs at the conclusion of the experiment (8 h) and compared to control rats thatwere infected but receivedno antibiotic (noABX) (***
p b 0.0001; unpaired t-test).
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remained infected as viable pathogens were detectable in the organs at
the end of the 36 h experiment (Fig. 3b). In contrast, the releasedmem-
brane PAMPs detected by the FcMBL ELLecSA steadily increased during
infusion, and remained elevated during the course of the infection
mirroring the increase in WBC count (Fig. 3a). No increase in PAMPs
was observed in control animals. As the blood cultures are negative
after 12 h, the PAMPs detected with the FcMBL ELLecSA after this time
in this model must result from cell wall fragments (e.g., blebs, LPS)
that are released by pathogens growing within solid organs. Thus, in
this large animal model, the PAMP levels detected in blood by the
FcMBL ELLecSA provided a determination of infection at distant sites,
even when live pathogens were not present within blood.
We also explored whether we could detect PAMPs in infected ani-
mals receiving antibiotic therapy using a rat infection model (Didar et
al., 2015). This model and dose were chosen because infected rats are
highly resistant to Escherichia coli, and thus, only exhibit low levels of
bacteria and PAMPs in blood when analyzed over a short time course
(b8 h) (Didar et al., 2015). When rats were injected with Escherichia
coli intraperitoneally and treated with either cefepime (100 mg/kg) or
saline 4 h later,we detectedmore than a 6-fold increase in release of bac-
terial PAMPs into the blood from the localized nidus of infection within
the peritoneum in antibiotic-treated rats using the FcMBL ELLecSA
(p b 0·0001) (Fig. 3c), even though blood cultures from these infected
animals were negative. Thus, these ﬁndings demonstrate that the
FcMBL ELLecSA can be used with standard of care antibiotic treatment,
whereas this is not possible using conventional blood culture assays or
molecular diagnostic assays that require the presence of live organisms.
4.4. Detection of infection in human subjects
To assess the potential value of the FcMBL ELLecSA as an infection di-
agnostic for patients at risk for developing sepsis, we analyzed blood
samples collected from prospectively enrolled patients at the BIDMC
Emergency Department, who were suspected to have an infection
based on their initial clinical presentation. Their blood PAMP values de-
tected by the FcMBL ELLecSAwere comparedwith results obtained from
two other patient cohorts — non-infected patients with non-infectious
etiologies of illness and non-infected patients presentingwith traumatic
injuries. 291 patients were enrolled in the study using medical criteria
outlined in theMethods section (Fig. 1).We imposed additional internal
assay validation limits as inclusion criteria: The ELLecSA had to be run
within 24 h of the blood draw (to ensure the sample was fresh), and as-
sayswere excluded if the internal standardmannan curve failed tomeetthe 95% conﬁdence interval for the slope and background (Supplemen-
tal Fig. 1). FcMBL ELLecSA data from 164 patients were included for
analysis: 78 patients who presented with suspected infection, 35 non-
infected controls, and 52 non-infected trauma patients (Table 2). Pa-
tient blood was assayed by culture and ELLecSA at study entry (0 h)
and 24 h later. The analysis revealed that the FcMBL ELLecSA detected
signiﬁcantly higher PAMPs in the clinically identiﬁed infection patient
cohort than the non-septic control cohort at both timepoints (Wilcoxon
Rank Sum test; p b 0.001 at 0 and 24 h) (Fig. 4a). When paired samples
of the same patients were analyzed at 0 and 24 h, there was much
broader range of values in the septic patients, however, the difference
between the mean values measured at the different time points were
foundnot to be signiﬁcant (Wilcoxon SignedRank test; pb 0·13) (Fig. 4b).
By carrying out a receiver operating characteristic (ROC) comparison
of each sepsis blood draw against non-infected controls, we determined
that the FcMBL ELLecSA threshold of N0.45 PAMP units was the optimal
threshold to distinguish infection from non-speciﬁc signals (Fig. 4c).
Based on this threshold, the accuracies of the FcMBL ELLecSA diagnostic
were determined to be 0.87 and 0.89 at 0 and 24 h, respectively (Fig 4d)
with an inter-assay coefﬁcient of variation of 12.9% (low 11.4%; high
14.4%) and an intra-assay coefﬁcient of variation of 8.3% (low 9.7%;
high 6.9%). At the initial blood draw, the ELLecSA sensitivity was 81%
and speciﬁcity was 89% (55/67 patients), and these increased to 85%
and 89% one day later (29/34 patients) when compared to blood sam-
ples from non-infected controls (Fig. 4d). In contrast, when we com-
pared these results to blood cultures as a method of direct detection of
bacteria, and for which molecular diagnostics have similar detection
rates (Bacconi et al., 2014; Knabl et al., 2016), the blood cultures only
Fig. 4. The FcMBL ELLecSA enables detection of patients with sepsis compared to healthy controls based on higher PAMP levels. (a) PAMP levels were signiﬁcantly increased in blood
samples from patients with suspected sepsis at both study entry (0 h) and 1 day later (24 h) compared with non-infected control donor samples (**, p b 0.001; Wilcoxon Rank Sum
test). (b) Change in PAMP scores for paired sequential blood samples at 0 and 24 h for sepsis patients (ns, no signiﬁcant difference; Wilcoxon Signed Rank Test). (c) Receiver operating
characteristic (ROC) comparison of the FcMBL ELLecSA data for sepsis patients versus non-infected controls. Areas under the ROC curve for sepsis patient bloods at 0 and 24 h were =
0.870 + 0.041 (mean + SEM; p b 0.0001) and 0.889 + 0.050 (p b 0.0001), respectively. (d) Performance characteristics of the FcMBL ELLecSA for detection of infection in patients
suspected of sepsis versus healthy non-infected controls using a PAMP threshold of N0.45 units, as determined by ROC analysis.
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The FcMBL ELLecSA detected infection in 11/12 of the blood culture pos-
itive samples and 7/8 patients with positive bacterial identiﬁcation cul-
tured from other (non-blood) biological samples (Supplemental Table
2) and the remaining 47 patients were culture negative. These results
demonstrate the FcMBL ELLecSA can detect infection in patients wheth-
er they are blood culture positive or negative.Fig. 5. The FcMBL ELLecSA enables detection of patients with sepsis compared to non-infected t
increased in blood samples from patients with suspected sepsis at both study entry (0 h) and
Wilcoxon Rank Sum test). (b) CRP levels measured in the same sepsis samples using a CRP E
study entry (0 h) and 1 day later (24 h) compared with non-infected trauma patient sam
performance characteristics of the FcMBL ELLecSA versus the CRP ELISA revealed that while b
performance characteristics were determined by ROC analysis of CRP ELISA data using a 5 mg/4.5. Performance of the FcMBL ELLecSA compared to the CRP assay
Current blood protein biomarker assays used for detection of sepsis
(e.g. CRP, PCT) are indirect in that theymeasure increases in the inﬂam-
matory response to infection, rather than the pathogens or toxins them-
selves (Chan and Gu, 2011). To determine if the FcMBL-based PAMP
assay offers greater speciﬁcity, we compared our ELLecSA with therauma patients. (a) PAMP levels were extremely low in trauma patients, and signiﬁcantly
1 day later (24 h) compared with non-infected trauma patient samples (***, p b 0.0001;
LISA also were increased in blood samples from patients with suspected sepsis at both
ples (***, p b 0.0001; *, p b 0.003; Wilcoxon Rank Sum test). (c) Comparison of the
oth assays have similar high sensitivity, the ELLecSA has a much higher speciﬁcity. CRP
ml cutoff value (Fig. 6).
Fig. 6.Receiver operating characteristic (ROC) curves used to compare the ability of the FcMBL ELLecSA and CRP assays to differentiate patientswith systemic infection or sepsis from those
with sterile trauma. Plasma extracted from the same patient samples analyzed by the FcMBL ELLecSAwere then diluted and analyzed using the CRP ELISA. (a) FcMBL ELLecSA. Areas under
the ROC curves at 0 and 24 h for the septic patient samples compared to those with traumawere 0.831+ 0.038 (p b 0.0001) and 0.867+ 0.045 (p b 0.0001); area under the ROC curve for
the non-infected control versus trauma was 0.589 + 0.061 (p b 0.156). (b): CRP ELISA. Areas under the ROC curves at 0 and 24 h for the septic patient samples compared to those with
trauma were 0.793+ 0.045 (p b 0.0001) and 0.740+ 0.063 (p b 0.003); area under the ROC curve for the non-infected control versus traumawas 0.741 + 0.064 (p b 0.0016). (c) FcMBL
ELLecSA PAMP levels were not signiﬁcantly increased in blood samples from patients with non-infected trauma compared with non-infected control (Wilcoxon Rank Sum test). (d) CRP
levels were signiﬁcantly increased in blood samples from patients with non-infected trauma compared with non-infected control (p b 0.0013; Wilcoxon Rank Sum test).
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ples from 52 non-infected trauma patients. The PAMP levels in blood
samples from this non-infected patient cohort measured using the
FcMBL ELLecSA were signiﬁcantly lower than those in patients with
clinically documented infection (p b 0·0001), with 25% (13/52) false
positives using the same threshold described above (N0.45 PAMP
units) (Figs. 5a; 6c), while the speciﬁcity of the FcMBL ELLecSA for pa-
tients with infection compared to those with non-infected trauma was
74% (Figs. 5c; 6a). The observed drop in sensitivity from 81% (versus
control) down to 74% (versus trauma) for detecting infectionmay result
from undocumented infection detected by FcMBL, as two of the non-in-
fected trauma patients later became blood culture positive (Table 2). In
contrast, while CRP levels also were higher in blood from infected pa-
tients (p b 0.0001 and b0.003 at 0 and 24 h, respectively) (Fig. 5b;
6d), use of the CRP assay resulted in a false positive rate that was almost
2 times higher (49%; 25/52) resulting in a low speciﬁcity of only 50% in
non-infected trauma patients (Figs. 5c; 6b). Taken together, these re-
sults conﬁrm that compared to the conventional CRP assay currently
used clinically, the FcMBL ELLecSA provides signiﬁcantly greater speci-
ﬁcity (74% versus 50%) to distinguish patients with infection from
those with trauma.
5. Discussion
The need for rapid and accurate diagnosis of infection is great as de-
layed administration of antimicrobial therapy increasesmortality by the
hour as the infection rapidly evolves from local infection to sepsis, and
eventually, to severe sepsis and septic shock (Martin et al., 2003;
Kumar et al., 2006; Ferrer et al., 2014; Liu et al., 2014). A positive
blood culture remains the current gold standard for laboratory diagno-
sis of systemic infection; unfortunately, most (N70%) septic patientshave negative blood cultures (Tsalik et al., 2012; Gille-Johnson et al.,
2013) and the sepsis and infection biomarkers currently in clinical use
that measure the patient's inﬂammatory status, such as CRP, are of lim-
ited value in patient populationswith inﬂammation induced by non-in-
fectious illnesses or trauma. Thus, to address the critical need for an
infection-speciﬁc biomarker that can assist physicians to decide on
whether hospitalization is critical, antibiotics should be administered,
or if recently developed dialysis-like sepsis therapies (Basu et al.,
2014; Tullis et al., 2010; Mitaka and Tomita, 2011; McCrea et al.,
2014) are appropriate, we leveraged the wide pathogen- and toxin-
binding capabilities of the engineered FcMBL opsonin (Kang et al.,
2014) to develop a broad-spectrum rapid diagnostic that directly de-
tects the presence of pathogen-released PAMPs in whole blood. The
FcMBL ELLecSA detects the cell wall materials of a broad range of living
and dead pathogens, including negative and positive bacteria, fungi, vi-
ruses and parasites. Importantly, in our studies with human subjects,
the FcMBL-based ELLecSA proved to be a sensitive and speciﬁc systemic
biomarker for infections, detecting PAMPs in N80% of blood samples
from emergency department patients with infection-related disease ae-
tiologies, even though b20% of these patients had positive blood cul-
tures. The FcMBL ELLecSA's ability to detect PAMPs directly also can be
leveraged to distinguish patientswith infection from thosewith non-in-
fection related inﬂammatory conditions. Our ability to use this PAMP
assay to discriminate between patients with infection and those with
trauma is in line with the new Sepsis 3 guidelines in which SIRS criteria
have been questioned because of issues related to determining the
source of infection (Singer et al., 2016). The PAMP infection diagnostic
also can be implemented in settings outside of central hospitals where
qSOFA/SOFA scores aremore challenging to determine, and it potential-
ly can enable clinicians to identify patients with infection even when
they have low qSOFA or SOFA scores in the hospital setting (Singer et
225M. Cartwright et al. / EBioMedicine 9 (2016) 217–227al., 2016). Thus, the FcMBL-based PAMP assaymay serve as a new rapid
diagnostic for infection in patients who are suspected to have a blood-
borne infection or early-stage sepsis, and thereby help to reduce unnec-
essary use of antibiotics.
One of the key ﬁndings of this study is that the FcMBL ELLecSA de-
tected PAMPs released from 47 of 55 (92%) clinically relevant pathogen
species screened, including 14 of 16 of the most frequent bacterial spe-
cies associated with sepsis at two major academic clinical medical cen-
ters (Brigham and Women's Hospital in Boston and Johns Hopkins
School of Medicine in Baltimore); the only exception was Enterococci,
which was responsible for less than 5% of these infections. The broad
spectrum of PAMP detection by the FcMBL ELLecSA was reﬂected in
our ability to rapidly (b1 h) detect N80% of infections in human patients
in our studywhether or not they were receiving antibiotic therapy. This
is in contrast to blood cultures that were positive in only 18% of these
same patients, which is similar to levels of detection reported in past
clinical studies (Tsalik et al., 2012; Gille-Johnson et al., 2013; Loonen
et al., 2014; Knabl et al., 2016; Bacconi et al., 2014). Indeed, the FcMBL
ELLecSA was not only able to detect infection, but to track infection in
near real time in our pig infection model regardless of blood culture re-
sults. Therefore, the FcMBL ELLecSA-based PAMP detection method po-
tentially offers a promising new way to assist physicians as a rapid
infection-speciﬁc diagnostic. In fact, based on animal studies (Didar et
al., 2015), it may even be possible to determine when bacteriocidal an-
tibiotics are effective in vivo by detecting an abrupt increase in PAMPs.
Two other infection biomarkers, the Limulus Amebocyte Lysate (LAL)
and Endotoxin Activity Assay (EAA), also detect one particular type of
PAMP (LPS) directly; however, they are not widely used because they
can only diagnose Gram negative infections (Marshall et al., 2004). In-
deed, the LAL Assay performed poorly as a diagnostic tool for patients
with suspected bacteremia (Hurley et al., 2015), likely due to assay en-
hancement or interference by components in complex biological sam-
ples, including blood (Bates et al., 1998). The EAA sepsis diagnostic is
also limited in its use because it must be run immediately following
the blood draw (Marshall et al., 2004). It can detect elevated signals in
septic patients with Gram negative infections compared to non-septic
patients (Mignon et al., 2014), but it is not often used clinically because
it lacks speciﬁcity (Marshall et al., 2004) and has limited effectiveness
in neutropenic patients (Romaschin et al., 2012). In addition, the EAA di-
agnostic has been shown to detect elevated levels of LPS in trauma pa-
tients resulting from gut leakage and antibiotic therapy (Charbonney et
al., 2016). Importantly, the levels of endogenous LPS released from the
gut that were reported in that study are below the detection limit of
our FcMBL ELLecSA (negative in the trauma cohort screened) and thus,
it should not complicate our assay. Further clinical testing of speciﬁc pa-
tient populations (e.g. post-surgery, and burn)will be required to further
optimize the assay threshold, and possibly identify speciﬁc threshold
subsets for each patient population. In addition, the FcMBL ELLecSA diag-
nostic described here can detect a wide variety membrane-associated
PAMPs (not just LPS) that are released into blood by Gram positive bac-
teria (e.g., lipotechoic acid), fungi, viruses and parasites, as well as by
Gram negative bacteria. The FcMBL ELLecSA is also much more resistant
to interference by components of biological ﬂuids than either the LAL
and EAA assays, and so it should be more valuable for clinical use.
Other biomarkers that measure the immune response to infection,
such as CRP and PCT, are increasingly being implemented for rapid de-
tection of sepsis (Chan and Gu, 2011; Carr, 2015; Albrich and
Harbarth, 2015; Prucha et al., 2015). CRP and PCT values have been
shown to be elevated in infections, with increasing levels correlating
with likelihood of infection and sepsis severity (Tsalik et al., 2012;
Loonen et al., 2014; Carr, 2015). However, it is difﬁcult to use these as-
says to distinguish between patients with sepsis versus sterile SIRS in
subpopulations of patients who have experienced surgery (Battistelli
et al., 2014; Stoppekamp et al., 2015; Uzzan et al., 2006; Kaukonen et
al., 2015), burn injury (Seoane et al., 2014), trauma(Wojtaszek et al.,
2014) or stroke (Li and Liu, 2015). In contrast, the unique clinical utilityof the FcMBL-enabled PAMP assay presented here is that in addition to
being able to rapidly and speciﬁcally detect the presence of infection in
whole blood samples, the PAMP assay can reliably distinguish patients
with infection from those with trauma-associated inﬂammation, there-
by giving physicians clinically valuable, actionable information. The
FcMBL ELLecSA could be used to direct therapy and determine the
need for further testing using molecular diagnostics in patient popula-
tions where risk of infection is elevated, but detection using these
existing inﬂammation-related biomarkers is ineffective or non-speciﬁc.
More accurate detection of the speciﬁc presence of infection using this
PAMP assay can further reduce the inappropriate use of antibiotics as
well. It also would help guide physicians as to when to initiate or stop
treatment with dialysis-like sepsis therapies that are speciﬁcally de-
signed to cleanse patient blood of pathogens and PAMPs, which either
have been recently approved for clinical use or are currently in develop-
ment (Didar et al., 2015; Basu et al., 2014;Mitaka and Tomita, 2011). Fu-
ture studies will help elucidate the sensitivity and speciﬁcity of the
FcMBL ELLecSA for these diverse applications and patient populations.
In the present study, the sensitivity of detection of the clinical iso-
lates in vitro by the FcMBL ELLecSA was enhanced upon release of
PAMPs by either mechanical disruption or treatment with bacteriocidal
antibiotics, and this correlated with the detection of PAMPs in blood
samples in both our studies with animals and human patients when
blood cultures were negative but infections remained present at distant
sites. These observations demonstrate that PAMPs released as a result of
immune cell killing reactions or antibiotic therapy can bedetectedwith-
in blood samples using the FcMBL ELLecSA assay. We could detect
PAMPs in blood samples of animals that were injected intravenously
with live pathogen, in animals that were injected locally in the peritone-
um with pathogens, as well as in blood culture-negative animals that
were later shown to have local infection sites within internal organs
(e.g., liver, spleen and lung). More importantly, we showed that we
could detect infections in blood culture-negative humans who demon-
strated clinical symptoms of sepsis. Thus, the FcMBL-based PAMP
blood assay clearly can be used to detect the presence of infections
where living pathogens are localized to speciﬁc organ sites as well as
blood-borne infections. While the assay cannot currently discriminate
between these types of infection, this could be explored in future stud-
ies (e.g., based on PAMP levels or analysis of their molecular composi-
tion). Also, although we did not detect a signiﬁcant increase in PAMP
signal in paired infection samples of patients between time zero
(when patients ﬁrst received broad spectrum antibiotics) and 24 h
post-admittance, the overall mean PAMP level appeared to increase be-
tween these time points, but a more targeted trial is needed to deter-
mine signiﬁcance. This raises the possibility that the FcMBL ELLecSA
could be used to track the efﬁcacy of antibiotic treatments in infected
patients in vivo, either alone or in combination with other biomarkers,
such as PCT, which are currently being explored as a means to monitor
antibiotic therapy for sepsis in the ICU (Carr, 2015; Schuetz et al., 2013;
Jensen et al., 2011).
Molecular diagnostics that purport to detect and identify speciﬁc
pathogens directly in blood are currently in development or entering
the clinic. For example, the molecular diagnostic T2Candida Panel (T2
Biosytems) has demonstrated improved speciﬁcity, sensitivity and
speed of detection (~4 h) for identifying invasive candidiasis in blood
culture negative patients (Mylonakis et al., 2015). But due to the low
frequency of fungal infections in septic patients, the assay faces chal-
lenges for adaptation into the clinic as a general screening test. While
the multiplexed PCR methods, SeptiFast (Roche, Diagnostics GmbH),
and hybcell® Pathogens (Anagnostics Bioanalysis GmbH), and the
PCR-ESI-MSmethod, IRIDICA (AbbottMolecular), can detect and identi-
fy bacteria and fungi in blood within 4–6 h with N90% sensitivity and
speciﬁcity in patients identiﬁed as positive by either blood culture or
PCR (Knabl et al., 2016; Bacconi et al., 2014), the sensitivity of these
assays drops dramatically to 10–40% for all patients with suspected
bloodstream infections (Knabl et al., 2016; Bacconi et al., 2014)
226 M. Cartwright et al. / EBioMedicine 9 (2016) 217–227(Supplemental Fig. 2). In contrast, the FcMBL ELLecSA alongwith immu-
noassays such as PCT, offer an even more rapid (b1 h) and generic test
for identiﬁcation of infection by a broad range of different types of path-
ogens. The FcMBL ELLecSA does not identify the speciﬁc type of patho-
gen; however, one can envision combining molecular diagnostic tools,
such as mass spectrometry, to distinguish speciﬁc pathogen types
based on the molecular composition of the captured PAMPs. This
assay is also unique in that quantiﬁcation of PAMP levels over time
also might be used to track antibiotic efﬁcacy in vivo without the need
for pathogen identiﬁcation (Carr, 2015; Schuetz et al., 2013; Jensen et
al., 2011), and thus, rapidly assist physicians in their selection of an op-
timal therapy.
In summary, the FcMBL-based ELLecSA offers a rapid, sensitive and
speciﬁc method for diagnosing a broad range of infections in patients
by directly quantifying the levels of PAMPs that initiate and fuel the in-
ﬂammatory cascade responsible for sepsis, whether present on living
pathogens or released as debris or toxins. Based on the promising sensi-
tivity and speciﬁcity the FcMBL ELLecSA for recognizing sepsis patients
in this pilot study, it is possible that it might be used to identify patients
whoare not responding to initial antibiotic therapies, and tohelp reduce
inappropriate usage of antibiotics in patient subpopulations (e.g. im-
mune compromised) who are at high risk for infection, but for whom
current inﬂammatory biomarkers are not useful due to their lack of
speciﬁcity. The FcMBL ELLecSA can be automated in a high-throughput
format amenable to pathology laboratories, as well as be adapted for
single use point-of-care settings. Most importantly, this simple test for
diagnosing systemic infections has the potential to provide clinically ac-
tionable information to inform physicianswhen patients should be hos-
pitalized, antibiotic therapies administered, or dialysis-like therapies
initiated, evenwhen blood cultures are negative. It also could potential-
ly be used to detect when bacteriocidal therapies are effective in vivo
(i.e., by detecting an abrupt increase in PAMPs immediately following
initiation of antibiotic therapy).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.06.014.
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